Jason Kline, MD
Nephrology · Camden, NJNPI 1912115296
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,082 of the $7,282 with a category attached, or 83.5%. Vifor Pharma, Inc. accounts for 66.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $1,802 and has fallen 69.5% since, to $549 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $105.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$5K
- Bayer$2K
- Akebia Therapeutics Inc$245
- Ardelyx, Inc.$142
- AstraZeneca$137
- Aurinia Pharma U.S., Inc.$117
- plus $172 from 5 others
What the payments were for
- Speaking & faculty fees$1,20016%
- Food & beverage$6,08284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 39 | $4,868 |
| Bayer | 14 | $1,601 |
| Akebia Therapeutics Inc | 3 | $245 |
| Ardelyx, Inc. | 2 | $142 |
| AstraZeneca(2 entities) | 3 | $137 |
| Aurinia Pharma U.S., Inc. | 2 | $117 |
| Calliditas Therapeutics US Inc. | 1 | $105 |
| Amgen(2 entities) | 2 | $25 |
| Fresenius USA Marketing, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,282 in reported general payments places this provider in the 90th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 23 | $75,481 |
| VelphoroSucroferric Oxyhydroxide | 18 | $42,977 |
| FarxigaDapagliflozin Propanediol | 22 | $27,123 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $17,901 |
| Sevelamer Carbonate | 40 | $9,580 |
| Torsemide | 169 | $3,566 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,135 |
| Eplerenone | 23 | $1,555 |
| Chlorthalidone | 72 | $1,551 |
| Calcium Acetate | 17 | $957 |
| Losartan Potassium | 49 | $731 |
| Colchicine | 11 | $572 |
| Nifedipine ErNifedipine | 16 | $551 |
| Calcitriol | 21 | $467 |
| Valsartan | 11 | $457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $16 | $42,97718 claims |
| AstraZenecaFarxiga | $137 | $27,12322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Camden
- Vinay SrinivasanCamden$17K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.